Supernus Pharmaceuticals (SUPN) Receives Tentative Approval for Trokendi XR™
6/10/2013 9:16:09 AM
More...
|
Supernus Pharmaceuticals (SUPN) Reports First Quarter 2013 Financial Results
5/14/2013 9:56:10 AM
More...
|
Supernus Pharmaceuticals (SUPN) Announces First Quarter 2013 Earnings Conference Call and Webcast
5/7/2013 9:52:25 AM
More...
|
Supernus Pharmaceuticals (SUPN) Announces Closing of $90 Million
5/6/2013 7:30:00 AM
More...
|
Supernus Pharmaceuticals (SUPN) Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019
4/26/2013 11:04:10 AM
More...
|
Supernus Pharmaceuticals (SUPN) Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast
3/8/2013 10:14:19 AM
More...
|
Supernus Pharmaceuticals (SUPN) Launches Oxtellar XR™ in the United States
2/1/2013 8:53:24 AM
More...
|
Supernus Pharmaceuticals (SUPN) Appoints Victor Vaughn as Senior Vice President of Sales
1/15/2013 9:09:58 AM
More...
|
Supernus Pharmaceuticals (SUPN) Announces Positive Phase 2 for ADHD
11/21/2012 6:49:41 AM
More...
|
Supernus Pharmaceuticals (SUPN) Receives Three Years of Market Exclusivity for Oxtellar XR™
11/19/2012 11:07:47 AM
More...
|
|